Corcept Therapeutics
CORT
Performance
About Corcept Therapeutics
Corcept Therapeutics advances cortisol modulation therapies focused on treating serious diseases by targeting the glucocorticoid receptor. The company conducts research and clinical development across endocrinology, oncology, metabolism, and neurology, aiming to unlock the therapeutic potential of cortisol modulation. Based in the United States, it communicates a commitment to scientific innovation and patient health through its pipeline and scientific publications.
Recent News
Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies
Corcept's Drug Extends Patients' Lives in Key Ovarian Cancer Study
BMS-986482
Ovarian Cancer Data Give Corcept’s Shares a Bounce After Year-End CRL Drop
Securities Lawsuits Target Corcept and Aldeyra, Sparking Investor Scrutiny
Corcept Investors Can Lead $100K+ Securities Fraud Suit by April 21
Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk
FDA Says It Explained Issues Early on for Corcept's Rejected Cushing's Syndrome Drug
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
Pfizer, Lilly, More Report Q1, FDA Names Acting CBER Director and an ALS Awakening
The US FDA New Drug Approvals in March 2026
Corcept Ties ALS Drug to Improved 2-Year Survival as Phase 3 Start Date Nears
Hypercortisolism Common in Patients with Resistant Hypertension
Corcept Presents Complete Data From Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Recent Deals
No recent deals for this company.